Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: Pipeline Data (PPDA)
http://www.investorshub.com/boards/board.asp?board_id=6422
Big Blue
Growth
This company has grown their merchant base dramatically over the past 2 year through acquisitions and organic growth.
Big Blue
Dear Moderators,
Don't you find something wrong with post: 47934.
Thank you for your time.
Big Blue
8K out.
7-Jul-2006
Entry into a Material Definitive Agreement, Creation of a Direct Financial
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On June 30, 2006, the Registrant issued to Dutchess Private Equities Fund, II L.P. ("Dutchess") a promissory note (the "Note") in the amount of $1,495,000 for a purchase price of $1,150,000.
As previously reported, on September 28, 2004, the Registrant entered into an Investment Agreement (the "Investment Agreement") with an affiliate of Dutchess, pursuant to which Dutchess has committed to purchase common stock of the Registrant up to an aggregate purchase price of $35 million over a two year period. The Dutchess Agreement provides that the Registrant from time to time may deliver a put notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of common stock set forth in the notice.
The Note is due and payable in full on June 29, 2007. Other than the discount inherent in its purchase price, the Note is noninterest-bearing. The Note will be repaid using 100% of the proceeds of each put notice delivered by the Registrant to Dutchess under the Investment Agreement. The Note is also secured by a security interest in substantially all of the Registrant's assets pursuant to a Security Agreement dated March 6, 2006 with Dutchess.
In connection with the Note, the Registrant also paid Dutchess a facility fee of $90,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $373,750 payable on June 29, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess's option at a conversion price equal to $0.01 per share.
Why would you attack Stockboy?
If one listened to Jever they would have lost a great deal of money. However, if someone listened to Stockboy over the last few months one would have saved money. Jever and others on this board that preached to buy and the price will go up soon are just as bad as those in the past that stated .0001 is coming. It truly is disgusting.
Although, this company has more irons in the fire than ever before it continues to dilute shares to stay alive and dilute to buy companies that do not have positive earnings. The only reason why a stock goes up or down is supply and demand. It doesn’t matter what the trigger for the accumulation or distribution is… be it value, growth, speculation, poor quarter, great year…the only reason a stock goes up is the squeeze on liquidity on the float during an accumulation period….that’s called demand. That’s it. With that being said DNAG's continued dilution is hurting the stock. Also, with the purchases of different companies, the exposure is nice and likely gets more people interested or introduced to the company; however, expanding revenue with exposure means little when you're expanding costs at a greater clip. I hope, like most purchases, these mergers will likely take 1 to 2 years for all synergies to come into focus, efficiencies to be realized, and relative expenses reduced....but this does not help us now. Do your own DD and you will see in the last quarterly that the Net Loss out paced Sales over the previous year. If this company continues to buy other non-profitable companies for stock while continuing to dilute share value to stay alive they many not reach 2011 to see 401 come to market. If you can't see that their expansion over the last year (although interesting) has hurt their chances to their now main goal, bringing super epo to market…you’re investing recklessly....do what you will.
Too many on this board sling too much crap without looking at the real details...this is one of the reasons I have stayed away for awhile. Everybody please read the quarterly statements. I am hopeful that one day this company will be profitable while improving the lives of those who the medicines are focused one…..and the pps rises accordingly until then I will hold on to a small core with the understanding as everyone here should have.....that it maybe a tax write off.
I can afford to be patience...everyone with this investment should be asking themselves if they can afford the loss.
God Bless,
Big Blue
DNAPrint Genomics CEO Tells Shareholders At Annual Meeting That 'Theranostic' Drugs Signal New Era in Medicine
Thursday June 22, 12:50 pm ET
SARASOTA, Fla., June 22, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) President and Chief Executive Officer Richard Gabriel told shareholders at the Annual Meeting today that the development of ``theranostic'' genetic test/drug combinations for treating diseases based on a human being's genetic profile signals a new era in medicine.
``Medicine is moving toward the customization of new drugs based on technologies that determine how a patient will respond to a prescribed treatment,'' Mr. Gabriel stated. ``Physicians and patients have much to gain from theranostics. A physician will be able to prescribe what will effectively constitute an appropriate drug and dosage to more precisely meet a patient's needs.''
The driving force behind research and development at the Company's DNAPrint Pharmaceuticals, Inc., subsidiary is a desire to provide patients drugs that go beyond the industry's one pill fits all concept. ``We are at the forefront of improving patient care with a number of theranostic drugs in various stages of research and development. These theranostic drugs are designed to maximize efficacy and minimize side effects for specific individuals and well-defined population sectors,'' Mr. Gabriel stated.
Pharmacogenomics has significant potential, according to the U.S. Human Genome Project: ``Instead of the standard trial-and-error method of matching patients with the right drugs, doctors will be able to analyze a patient's genetic profile and prescribe the best available drug therapy from the beginning. Not only will this take the guesswork out of finding the right drug, it will speed recovery time and increase safety as the likelihood of adverse reactions is eliminated. Pharmacogenomics has the potential to dramatically reduce the estimated 100,000 deaths and two million hospitalizations that occur each year in the United States as the result of adverse drug response.''
DNAPrint's first pharmaceutical product in the pipeline is PT-401, a more potent and longer-acting form of Erythropoietin, an established anemia treatment drug. ``A Super EPO would open up a significant opportunity for DNAPrint Pharmaceuticals as Erythropoietin represents an $11 billion worldwide market that has been growing at an average annual rate of 18% for the past five years,'' stated Hector J. Gomez, M.D., Ph. D., the Company's Chairman and Chief Medical Officer. ``We are currently preparing for a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) to discuss the preclinical studies for PT-401.
``Other therapies in our product pipeline include Ritalin(tm)-like compounds for the potential treatment of drug abuse, attention deficit hyperactivity disorder (ADHD), and depression,'' Dr. Gomez said. ``These compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing the potential for cardiovascular complications, abuse and a patient's required daily dosage.''
Tony N. Frudakis, Ph. D., the Company's founder and Chief Scientific Officer, also addressed the Company's focus on pharmacogenomics. ``Our future ability to develop pharmacogenetics tests depends on what we learn today from our drug studies and the drug studies made by other companies. We believe that smart drugs will reshape what is currently a broken pharmaceutical model that does not best serve the patient population.''
Mr. Gabriel, turning to other key business segments, said that sales are steadily increasing for AncestrybyDNA(tm)`` a popular consumer product for determining family heritage. ''Recent media articles and television coverage about genealogy's growing popularity are generating sales for our product among people who want to know more about their family background,`` Mr. Gabriel said. ''As for the forensic aspect of DNA testing, DNAPrint is currently playing an active role in 109 police investigations worldwide. Our DNAWitness(tm) technology for the forensics and law enforcement market has been involved in numerous high-profile crime investigations and has received a significant amount of attention from the media as well.``
Shareholders attending the Annual Meeting and those voting by proxy re-elected the three-members of the Board of Directors. In addition to Mr. Gabriel, they are Dr. Gomez and Dr. Frudakis.
Shareholders also ratified the appointment of Pender, Newkirk and Company as DNAPrint's independent auditor for the fiscal year ending Dec. 31, 2006.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a ``Super EPO'' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to http://www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness(tm), RETINOME(tm), AncestrybyDNA(tm) and EuroDNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Dr. Frudaky,
Your excerpt is one of the main points of my agreement with Frog and its why I thanked him. If one understands how an IPO works, DNAG will still very likely have major dilution and add to the float. If the PPS goes up we would see less dilution but they would likely still need to sell shares to stay operational. DNAG could sell the Bio shares for cash but I don't think that they would sell too much because their partial buy-in bought a board seat at Bio... I would think that they would want to keep that for possible future deals/mutual interests.....selling all the shares may not mean the loss of the seat but it would not help.
Regards,
Big Blue
Dr Frudaky,
Well then please read Frogdreaming's post 46580. This is the post that I thanked him for because I was going to write near the same thing that he did.
Regards,
Big Blue
IF you wish to report jever000, Dr. Dew, or others who post emphatic claims on this stock to the SEC.
Here is the email address:
enforcement@sec.gov
Regards,
Big Blue
Disclosure: Holding
dr frudaky,
I think you need to go back and look at my post again.
Regards,
Big Blue
Jever's,
Why don't you disclose your full position?
Big Blue
Thank you Frog,
I was going to take the time to write out an email that outlines and explains the same points that you brought up to Dr. Dew who also wrote (46528):
dr frudacky,
I would say that is not correct. Once Biofrontera IPO's Dnag will use the proceeds to supply their company with the cashflow they need. Which means no more selling...I hope you are prepared for the most obvious outcome which IMO will be a large jump in share price. This is all based on of course the large following that biofrontera has in Germany.
Its inevitable folks...The SP will be higher soon.
Dr Dew
Thank you for saving me the time.
Regards,
Big Blue
The only reason why a stock goes up or down is supply and demand. It doesn’t matter what the trigger for the accumulation or distribution is be it value, growth, speculation, poor quarter, great year…the only reason a stock goes up is the squeeze on liquidity on the float during an accumulation period….that’s called demand. That’s it. DNAG’s main problem on this issue is dilution.
Wish I could play the way I use to on this board but 2 little ones demand my time.
Hopeful for all,
Big Blue
IF you wish to report jever00 to the SEC.
Here is the email address:
enforcement@sec.gov
His last post is against the law and if you want to send the SEC an email just ref. the post, site, and jever00.
Big Blue
Frog,
Thank you for the history.
Big Blue
Okay, I’ll bite….Why?
I understand that to be the longterm plan too but there is always a ramp up period with these types of transitions. As to how long it takes for 100% to move over to Trace....I have no idea.
Big Blue
Dear Frog,
I completely agree and I hope you’re right that this machine gets good time on the R&D side too. I reread my post and saw that it can be easily translated to more work means more revenue, and as you point out this is not likely the case, thank you. The one thing you can say for sure is that more work means greater efficiency realized. So, if there is a bottleneck of product work and if this machine cuts significant time off of each job there is more time available for R&D.
Big Blue
Dear Dnaowner,
I believe that you are referencing the upgrade of the Beckman Coulter GenomeLab. From data points from Tony and Money’s report of Trace, DNAG is reportedly flooded with work. The upgrade obviously cost money but I do believe that this could be a good purchase if the aforementioned data points continue to hold true. This is not a question of veracity but a question of sustained work. With sustained and incremental increases in work the breakeven moves up on the cost benefit analysis that DNAG hopefully did prior to the purchase and your efficiencies will really materialize. Contrary, if the work in is not sustained than you have a great & fast machine but all day to run the job(s)….the machine would sit idol most of the day.
I hope that you are right and there is a major bottleneck.
Big Blue
Wrong!
Jever did NOT get it right. Shall we review: 1) He said between Wednesday and Friday; 2) He said BIG news. 3) and lets not forget about his pps prediction. Of course after Friday came and went he moved his prediction. It is absolutely absurd that any of you are giving credibility to the Jever’s of this board. He is just one of many on this board in the recent past that have gotten it wrong with their predictions (just like e-med, brother-in-arms, go-dnap). How about we stick to the facts and potential of this company. This news is very minor. Yes, it stands to reason that the more people know the more inclined they will be to use their products but this organization is not an open retail business with store fronts all over the country. Therefore, you are not going to see revenue go up and up quickly from a marketing effort. They would have been MUCH better severed to announce a cost cutting initiative. This would be the one thing that they can attack now that would increase earnings.
Big Blue
The Bio Bar Code Patent...
is already owned by GenVault:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/search....
Perhaps the Trace pending is different? I ran about 20 searches over the last week and could not find it. However, I did come by GenVault's which appears to be closely related to Ripan's comments in the Red article.
Big Blue
GenVault Acquires Exclusive Patent to DNA Labeling Technology
Company gains unique position after purchasing the rights to nucleic acid labeling patent
San Diego, May 11, 2005 - GenVault, the leader in integrated biosample management, today announced an exclusive agreement to acquire the full rights to the DNA labeling intellectual property invented by Nigel S. Atkinson and Brain K. Haarer, researchers at the University of Texas. This patent allows GenVault to offer and license GenCode, its DNA labeling technology, to a broader market and positions it as the only company to offer double labeling for nucleic acid samples. This technology makes it possible for scientists to identify the sample through its complete downstream analysis to maintain a permanent chain of custody.
“Acquiring this patent is a valuable acquisition for GenVault as we expand into new markets,” commented David Wellis, senior vice president, marketing and sales for GenVault. “DNA labeling has been an integral part of our system that improves upon current biosample labeling techniques.”
Establishing and maintaining the correct identity of biosamples is critical to the integrity of research studies, human identity tracking, forensics and diagnostic testing. The advantage GenCode offers is a barcode that permanently identifies each biosample and remains with the sample even after it is removed from its container and eluted from its original storage medium. Therefore, a sample can be traced back to the original sample regardless of its physical state. To validate the potential effectiveness and benefits of their GenCode technology, GenVault recently published a peer-reviewed paper in Cell Preservation Technology (3: 54-59, 2005) titled "A DNA-based biological sample tracking method” that details the GenCode process and its uses in biosample storage.
The patented technology, U.S. Patent No. 6,153,389, is used as a direct mechanism for marking biological samples (blood, semen, saliva, etc.) that are to be used for subsequent DNA analysis. This process provides a distinctive identifying label for collected biosamples in future identification.
About GenVault
GenVault is the leader in integrated biosample management. The company currently provides integrated archiving and retrieval solutions for organizations managing DNA collections. GenVault aims to serve customers including medical centers, academic institutions, pharmaceutical companies, and law enforcement agencies. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. As a scalable and reliable alternative to traditional freezer networks and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation and recovery of DNA at room temperature. This novel sample management solution is configured for each customer's workflow and the planned growth of their biosample archive. In December 2004, GenVault was named as one of Red Herring’s Top 100 Innovators. From its GenPlate to its Dynamic Archive solution, GenVault is continuously developing and refining best practices for integrated biosample management.
There is much that can be derived from this article.
Big Blue
http://tracegenetics.com/redherring06_10_04.pdf
Stakddek,
Well written. You are turning into the Steven King of the board... quantity and quality.
I'm with you. I have paid my price to be admitted to the shaw and don't want to miss a moment of the saga. I have a relatively low cost base. I am invested in this company. I have hope.
Big Blue
Hey Cosmic,
As I’ve told you before, I think it’s great that you keep that list updated and it’s helpful for all of us. I looked and did not come up with extra projects….sorry. I like your list so much that I’ve championed the cause to have your list added to the intro board on a couple of different occasions (as well as other changes) but I’ve never gotten an answer. …never hurts to ask.
Big Blue
Dear Team,
I live in Troy. Troy is one town north of Tipp City on 75. If you like baseball and you come into town early September you should try and take in a Dayton Dragons game. The Dragons are a Single-A team for the Reds. I would rec. other stuff but since you have family in the area I'm sure that they'll take good care of you.
Big Blue
Staddek,
Great Post! I agree with almost everything you stated. Option 3 had me LOL!
One point I would add…......you wrote:
Meanwhile, the price per share decreases and each sale of shares at this low pps causes more proportionate dillution. Time is the enemy and each day without significant revenue, or firm contract promising the same is hurtful for us all, investors and management alike. To propose that management is unaware or uncaring of this situation is simply a false statement by some, or a misinterpretation of the business "facts of life" by others. Given posting histories available here, you can apply the appropriate labels, and determine for yourselves the weight to give to the opinions expressed, by me, or any others.
I would add that the desire to succeed does not equal success. You clearly point this out with Doctor Tony’s early attempts at CEO. Moving to modern day I completely agree that without this team we likely would not be here and I have little doubt as to their desire to succeed. The current main question that I have is that our current team has bought 1 company and part of another that both appear to be losing money. As you point out the pps is going down in part due to dilution. Well, part of the dilution issue now is paying for these companies. Bio may pay for itself with an offering or hidden gems but we have to wait and see. It appears that Trace has not only added to our dilution through the purchase but may have added to our continual dilution due to possible negative earnings. The total wisdom of these two moves may or may not be revealed in the next quarterly or for years for that matter; therefore, I’ll reserve further judgment until a later time. As for now I am hopeful for EPO, concerned about earnings, and long on patience. Once again, your last two big posts have been great!
Big Blue
Stockboy,
O-H
Money. Thanks for the report.
Big Blue
...Not by me Doctor. Jever has already proved himself to be a liar.
Big Blue
Hey Dorsey,
I don’t think its too strange for DNA. I’ve followed this story pretty close because I have an options position in Eyetech (post downfall). DNA has had so many good stories and such a great run with Avastin that people are going to take profits some days and today was likely such a day. Plus the news on Lucentis hit hard for DNA back in may (it was already priced in) and DNA is up 10 points since. Where as Eyetech’s Macugen has been on the market and people are selling off like crazy. All things being equal (vision improvement is still suspect) patients if given the choice would select getting stuck in the eye every 6 weeks over every 4….this would lead me to believe that Macugen will keep a good market share if Lucentis comes to market. JMHO.
I’m going to bed….too tired…good night,
Big Blue
OT: Hey Money,
Since you told me about it I initially looked pretty hard at it. At that time I had 10K to invest and I invested all of it in Calpine (CPN). I got in at 1.96 and sold 2500 shares at 3.28 and current have a limit order in place to option out 10 contracts to reduce my cost per share even more (I current have 2600 shares left and don’t want to option out all of them). I’ve done well with CPN so far and have played it and done well with it in the past too. I think I picked Calpine over PPHM mainly because I was more familiar with CPN. I haven’t forgotten your recommendation of PPHM and may jump-in in the future. I hope PPHM has done well for you. I saw that you had a nice 14% gain today! I don’t play as much as I used to otherwise I would’ve played both…I have a 17 month old to think about these days and that’s changed my investment strats just a bit. Once again, best of luck to you and thanks for checking in.
Big Blue
Thanks Dorsey!! That works great! Thanks!
Blue
Dear Moderators,
Perhaps others have suggestions for our introduction board but I have two simple requests. My two main suggestions are a link to Cosmics pipeline information since I can’t seem to get to it anymore through DNAG’s site and changing the following. Thanks for the consideration.
Big Blue
Our introduction board reads
DNAPrint Genomics ( OTCBB: DNAP ): DNAPrint is a biotech informatics platform business, and is involved in research and development. In addition, DNAP is a pharmacogenomics company with applications for patients, doctors, hospitals, forensics and the pharmaceutical industry. DNAP address:
DNAPrint Genomics
900 Coconut Ave. Sarasota, FL 34236
(941) 366-3400
Could we change this to (from our latest pr):
DNAPrint genomics, Inc. ( OTCBB: DNAG ): ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests.
Anytime Frog.
Blue
Hi Frog,
My understanding is that the maximum that you are referring to in your post is an estimate for calculating the registration fee only. The estimate is normally taken the a day to a week before the filing of the r/s but its normally for a single day; therefore, if the pps post split range for the day in question is from 15 to 19 the maximum would be 17 for registration fee purposes.
You wrote: If the pps goes higher than that, will the shares still be transacted at a maximum price of .17 cents or will there need to be a new filing to accomodate a higher price? One would hope that if the pps exceeded that value, then Dutchess would have to buy the shares at a discount to market price and not the fixed price from the filing.
My understanding is that DNAG would not have to refile. Also, Dutchess buys DNAG shares at 96% of the average of the two lowest closing bid prices during a trading period. This period is during a 5 days period after DNAG gives Dutchess a put notice. Therefore, I do not think Dutchess will be buying DNAG shares at a fixed price.
Hope this helps,
Big Blue
No No Steve you're funny when you drink...just don't get drunk..I'd hate to see what you'd post then.
Big Blue
Way OT: CPN
Big Blue
Sunday July 17, 8:50 pm ET
Grid Operator Urging Conservation as Power Usage Soars Over the Weekend
Monday, July 18: Flex Your Power NOW Day
FOLSOM, Calif.--(BUSINESS WIRE)--July 17, 2005--Sunday's peak demand of approximately 40,405 megawatts set a Sunday record for energy use in California and marked the first time that demand topped 40,000 megawatts for seven days in a row. That string of high demand days will continue on Monday, July 18 with a peak demand forecast of 45,988 Megawatts. The ISO predicts there will be enough power available to meet that demand, however, when demand is that high, there are fewer options available to deal with the unexpected -- such as the loss of a major power plant, or a transmission line tripping out of service. Subsequently, the ISO is declaring Monday a Flex Your Power NOW day, and is urging Californians to reduce their energy usage especially during the afternoon peak demand hours of 3:00 to 6:00 p.m.
Stage One Alert: possible Stage Two Alert: unlikely
Stage Three Alert: unlikely
Powerful Habits:
-- Set Thermostat at 78 or higher
-- Cool with fans
-- Draw the drapes
-- Turn off unnecessary lights and appliances
-- Use big appliances early in the day, or later at night
Stage One Emergency
Consumers are urged to reduce their use of electricity voluntarily to
avoid severe conditions.
Stage Two Emergency
Voluntary interruption of service to select customers is possible to
avoid more severe conditions.
Stage Three Emergency
Consumers are advised that involuntary interruptions of service have
begun and will continue until the emergency has passed.
Gratli,
Any of those would be great. You know over the last few years DNAG has put out their quarterly around 8-15. First quarter was an improvement in a few areas so I'm hopeful for the next 8-15. Also, I'm hopeful that they make it a touch more palatable a read over the last S-2.
I know I thanked you before for the shareholders meeting transcripts, but I wanted to thank you again. Over the weekend I reread your post/transcript on the investor web site and that information was great to see again. Thank you for the time invested.
Big Blue
It would be great if we got a progress report on both of these projects.
Big Blue
Ann writes:
VERY COOL! Confirms that Oprah took the DNAP's Ancestry by DNA:
This is a lie. Oprah took a mitochondrial DNA test. Ann I've found that you've done this at least on one other occation where your exuberance for the DNAG's cause gets the better of your judgement. This time I won't question your intent and will just attribute it to being a touch hasty.
Big Blue
Long Investor